Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In this issue of Cell Chemical Biology, Zhang et al.1 report the identification of a high-affinity EMBOW-derived inhibitor of WDR5, Ac7, which demonstrates in-cell target engagement and in vivo antileukemic efficacy. The microprotein-inspired inhibitor potently blocks the WDR5-MLL1 interaction, suppressing H3K4 methylation and transcription of target genes in mixed lineage leukemia (MLL)-rearranged leukemia.

Original publication

DOI

10.1016/j.chembiol.2025.10.010

Type

Journal article

Journal

Cell Chem Biol

Publication Date

20/11/2025

Volume

32

Pages

1305 - 1307

Keywords

Myeloid-Lymphoid Leukemia Protein, Histone-Lysine N-Methyltransferase, Humans, Leukemia, Intracellular Signaling Peptides and Proteins, Transcription, Genetic, Animals, Antineoplastic Agents